Mass spectrometry and molecular modeling studies on the inclusion complexes between alendronate and β-cyclodextrin

被引:13
作者
Biernacka, Joanna [1 ]
Betlejewska-Kielak, Katarzyna [2 ]
Witowska-Jarosz, Janina [2 ]
Klosinska-Szmurlo, Ewa [1 ]
Mazurek, Aleksander P. [1 ,2 ]
机构
[1] Med Univ Warsaw, Dept Drug Chem, PL-02097 Warsaw, Poland
[2] Natl Med Inst, PL-00725 Warsaw, Poland
关键词
beta-Cyclodextrin; Alendronate sodium; Inclusion complex; Mass spectrometry; Electrospray ionization; Molecular modeling; SPECTROSCOPIC INVESTIGATIONS;
D O I
10.1007/s10847-013-0315-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Complexation of alendronate sodium (AlnNa) with b-cyclodextrin (beta-CD) was studied by means of ESI-mass spectrometry. The experimental results show that stable 1:1 inclusion complexes between selected bisphosphonates and beta-CD were formed. In addition, complexes with different stoichiometry were observed. DFT/B3LYP calculations were performed to elucidate the different inclusion behavior between alendronate and beta-CD. Molecular modeling showed that the inclusion complex of Aln-beta-CD where the two phosphonate groups bound to the central carbon atom of bisphosphonate were inserted into the cavity of beta-CD from its "top'' side was thermodynamically more favorable than when they were inserted from its "bottom'' side; the complexation energy was -74.05 versus -60.85 kcal/mol. The calculations indicated that the formation of conventional hydrogen bonds was the main factor for non-covalent beta-CD:Aln complex formation and stabilization in the gas phase.
引用
收藏
页码:437 / 443
页数:7
相关论文
共 26 条
[1]  
[Anonymous], 2008, WAV SPART 08 WAV IRV
[2]   NMR studies of the inclusion complex between β-cyclodextrin and paroxetine [J].
Bernini, A ;
Spiga, O ;
Ciutti, A ;
Scarselli, M ;
Bottoni, G ;
Mascagni, P ;
Niccolai, N .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 22 (05) :445-450
[3]   Spectroscopic investigations and crystal structure from synchrotron powder data of the inclusion complex of β-cyclodextrin with atenolol [J].
Borodi, Gheorghe ;
Bratu, Ioan ;
Dragan, Felicia ;
Peschar, Rene ;
Helmholdt, Robert B. ;
Hernanz, Antonio .
SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2008, 70 (05) :1041-1048
[4]   Encapsulation of serotonin in β-cyclodextrin nano-cavities: Fluorescence spectroscopic and molecular modeling studies [J].
Chaudhuri, Sudip ;
Chakraborty, Sandipan ;
Sengupta, Pradeep K. .
JOURNAL OF MOLECULAR STRUCTURE, 2010, 975 (1-3) :160-165
[5]   Cyclodextrin-based pharmaceutics: Past, present and future [J].
Davis, ME ;
Brewster, ME .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (12) :1023-1035
[6]   Esophagitis associated with the use of alendronate [J].
deGroen, PC ;
Lubbe, DF ;
Hirsch, LJ ;
Daifotis, A ;
Stephenson, W ;
Freedholm, D ;
PryorTillotson, S ;
Seleznick, MJ ;
Pinkas, H ;
Wang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1016-1021
[7]   Cyclodextrins and their uses: a review [J].
Del Valle, EMM .
PROCESS BIOCHEMISTRY, 2004, 39 (09) :1033-1046
[8]  
Fleisch H., 2000, Bisphosphonates in bone disease: From the laboratory to the patient
[9]  
Fromming K.-H., 1994, TOPICS INCLUSION SCI, V5
[10]   STUDIES OF THE ORAL BIOAVAILABILITY OF ALENDRONATE [J].
GERTZ, BJ ;
HOLLAND, SH ;
KLINE, WF ;
MATUSZEWSKI, BK ;
FREEMAN, A ;
QUAN, H ;
LASSETER, KC ;
MUCKLOW, JC ;
PORRAS, AG .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (03) :288-298